PSYG Stock Overview
A life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Psyence Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.02 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.01 |
| Beta | 2.04 |
| 11 Month Change | 33.33% |
| 3 Month Change | -33.33% |
| 1 Year Change | -66.67% |
| 33 Year Change | -88.89% |
| 5 Year Change | n/a |
| Change since IPO | -96.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| PSYG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 33.3% | -2.9% | 2.2% |
| 1Y | -66.7% | -5.4% | 23.4% |
Return vs Industry: PSYG underperformed the Canadian Biotechs industry which returned -8.6% over the past year.
Return vs Market: PSYG underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
| PSYG volatility | |
|---|---|
| PSYG Average Weekly Movement | 55.6% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: PSYG's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: PSYG's weekly volatility has increased from 50% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | n/a | psyence.com |
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions.
Psyence Group Inc. Fundamentals Summary
| PSYG fundamental statistics | |
|---|---|
| Market cap | CA$2.80m |
| Earnings (TTM) | -CA$65.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PSYG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSYG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$65.89m |
| Earnings | -CA$65.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -113.1% |
How did PSYG perform over the long term?
See historical performance and comparison